Dyskeratosis congenita and the DNA damage response

被引:28
|
作者
Kirwan, Michael [1 ]
Beswick, Richard [1 ]
Walne, Amanda J. [1 ]
Hossain, Upal [1 ]
Casimir, Colin [2 ]
Vulliamy, Tom [1 ]
Dokal, Inderjeet [1 ]
机构
[1] Queen Mary Univ London, Barts & London Childrens Hosp, Barts & London Sch Med & Dent, Ctr Paediat, London E1 2AT, England
[2] Middlesex Univ, Sch Hlth & Social Sci, London N17 8HR, England
基金
英国惠康基金;
关键词
cell cycle; DNA damage; dyskeratosis congenita; lymphocytes; telomeres; TELOMERE LENGTH; CELL-CYCLE; MUTATIONS; COMPONENT; PROLIFERATION; GENE; RNA; SHELTERIN; DIAGNOSIS; BLOCKAGE;
D O I
10.1111/j.1365-2141.2011.08679.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>Dyskeratosis congenita (DC) is a heterogeneous bone marrow failure disorder with known mutations in components of telomerase and telomere shelterin. Recent work in a mouse model with a dyskerin mutation has implicated an increased DNA damage response as part of the cellular pathology, while mouse models with Terc and Tert mutations displayed a normal response. To clarify how these contradictory results might apply to DC pathology in humans, we studied the cellular phenotype in primary cells from DC patients of several genetic subtypes, focussing on T lymphocytes to remain close to the haematopoietic system. We observed novel cell cycle abnormalities in conjunction with impaired growth and an increase in apoptosis. Using flow cytometry and confocal microscopy we examined induction of the DNA damage proteins gamma-H2AX and 53BP1 and the cell cycle protein TP53 (p53). We found an increase in damage foci at telomeres in lymphocytes and an increase in the basal level of DNA damage in fibroblasts, but crucially no increased response to DNA damaging agents in either cell type. As the response to induced DNA damage was normal and levels of global DNA damage were inconsistent between cell types, DNA damage may contribute differently to the pathology in different tissues.
引用
收藏
页码:634 / 643
页数:10
相关论文
共 50 条
  • [1] Response to androgen therapy in patients with dyskeratosis congenita
    Khincha, Payal P.
    Wentzensen, Ingrid M.
    Giri, Neelam
    Alter, Blanche P.
    Savage, Sharon A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (03) : 349 - 357
  • [2] Multisystemic Manifestations in Rare Diseases: The Experience of Dyskeratosis Congenita
    Callea, Michele
    Martinelli, Diego
    Cammarata-Scalisi, Francisco
    Grimaldi, Chiara
    Jilani, Houweyda
    Grimaldi, Piercesare
    Willoughby, Colin Eric
    Morabito, Antonino
    GENES, 2022, 13 (03)
  • [3] DNA Damage Responses and Oxidative Stress in Dyskeratosis Congenita
    Pereboeva, Larisa
    Westin, Erik
    Patel, Toral
    Flaniken, Ian
    Lamb, Lawrence
    Klingelhutz, Aloysius
    Goldman, Frederick
    PLOS ONE, 2013, 8 (10):
  • [4] Dyskeratosis congenita
    Bessler, Monica
    Wilson, David B.
    Mason, Philip J.
    FEBS LETTERS, 2010, 584 (17) : 3831 - 3838
  • [5] Recent progress in dyskeratosis congenita
    Nishio, Nobuhiro
    Kojima, Seiji
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 92 (03) : 419 - 424
  • [6] Cancer in dyskeratosis congenita
    Alter, Blanche P.
    Giri, Neelam
    Savage, Sharon A.
    Rosenberg, Philip S.
    BLOOD, 2009, 113 (26) : 6549 - 6557
  • [7] A patient with dyskeratosis congenita and portal hypertension
    Wei, Min
    Liu, Yuanyuan
    Li, Jinhou
    Wang, Hongxia
    Gao, Yanjing
    PORTAL HYPERTENSION & CIRRHOSIS, 2023, 2 (02): : 101 - 104
  • [8] Dyskerin Mutations Present in Dyskeratosis Congenita Patients Increase Oxidative Stress and DNA Damage Signalling in Dictyostelium Discoideum
    Rodriguez-Centeno, Javier
    Perona, Rosario
    Sastre, Leandro
    CELLS, 2019, 8 (11)
  • [9] Dyskeratosis congenita
    Handley, TPB
    McCaul, JA
    Ogden, GR
    ORAL ONCOLOGY, 2006, 42 (04) : 331 - 336
  • [10] Advances in the understanding of dyskeratosis congenita
    Walne, Amanda J.
    Dokal, Inderjeet
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 (02) : 164 - 172